Benzhydrocodone/paracetamol

Drug Profile

Benzhydrocodone/paracetamol

Alternative Names: Acetaminophen/benzhydrocodone; Acetaminophen/KP-201; Apadaz; APAP/KP-201; Benzhydrocodone/acetaminophen; KP-201/acetaminophen; KP-201/APAP; Paracetamol/benzhydrocodone; Paracetamol/KP-201

Latest Information Update: 19 Oct 2016

Price : $50

At a glance

  • Originator KemPharm
  • Class Acetanilides; Antipyretics; Benzoates; Epoxy compounds; Morphinans; Non-opioid analgesics; Opioid analgesics; Opioid peptides; Small molecules
  • Mechanism of Action Opioid receptor agonists; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Acute pain

Most Recent Events

  • 18 Oct 2016 KemPharm in-licenses Aversion® Technology from Acura Pharmaceuticals
  • 08 Sep 2016 In-vitro pharmacodynamics data released by KemPharm
  • 13 Jun 2016 US FDA issues a complete response letter for the NDA application of benzhydrocodone/paracetamol in Acute pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top